Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

China Province Hits Medical Graft

From the China Compliance Digest (Issue No. 8: March 26, 2012):

Officials in the southern province of Yunnan announced the approval of regulatory changes designed to stem medical corruption, including the introduction of a blacklist of bribery offenders.
 
Facilities, companies, and personnel implicated in corruption will be ineligible for official commendations. In addition, doctors involved in serious corruption cases may have their medical licenses revoked.
 
Pharmaceutical companies involved in serious corruption cases will be barred from submitting products to the health department for approval.
 
Source: Health Paper (健康报)

________________

For a limited time, subscribers to the FCPA Blog will receive a complimentary one-month subscription to the China Compliance Digest. Subscribe to the FCPA Blog by filling in the box on the left under ‘Connect.’

Share this post

LinkedIn
Facebook
Twitter

Comments are closed for this article!